RP4-737E23.4 and LINC00656: Potential Drug Targets for Cancer and Other Diseases

Target Name: LINC00656

NCBI ID: G200261

LINC00656

Other Name(s): RP4-737E23.4 | long intergenic non-protein coding RNA 656 | Long intergenic non-protein coding RNA 656

RP4-737E23.4 and LINC00656: Potential Drug Targets for Cancer and Other Diseases

LINC00656 (RP4-737E23.4) is a drug target (or biomarker) that has been identified and characterized for its potential in the treatment of various diseases, including cancer. LINC00656 is a small non-coding RNA molecule that has been shown to play a role in the regulation of gene expression in various organisms, including humans.

One of the key features of LINC00656 is its ability to interact with the RNA-protein complex known as RNA-protein interactions (RPs) in the cell. RPs are a common interaction between RNA molecules and proteins, and they play a crucial role in the regulation of gene expression. LINC00656 has been shown to interact with a variety of RPs, including RP4-737E23.4, which is a protein that is expressed in various tissues and cells of the body.

TheRP4-737E23.4 protein is a key component of the RNA-protein complex that is responsible for the regulation of gene expression in various organisms. It has been shown to interact with a variety of RNA molecules, including LINC00656. This interaction between RP4-737E23.4 and LINC00656 suggests that the protein may be a potential drug target (or biomarker) for the treatment of diseases that are characterized by the over-expression of certain genes.

In addition to its potential as a drug target, LINC00656 has also been shown to have a variety of potential applications in the field of cancer research. For example, it has been shown to be downregulated in various types of cancer, which suggests that it may be a potential therapeutic target for these diseases. Additionally, LINC00656 has been shown to be involved in the regulation of cell apoptosis, which is a process that is involved in the natural death of cells in the body. This suggests that it may be a potential therapeutic target for diseases that are characterized by the failure of cells to apoptose.

Overall, LINC00656 is a promising drug target (or biomarker) for the treatment of a variety of diseases. Its ability to interact with the RNA-protein complex known as RPs, as well as its potential as a therapeutic target for cancer and other diseases, makes it an important area of research for scientists to explore further. Further studies are needed to fully understand the potential of LINC00656 as a drug target and to determine the best way to use it in the treatment of various diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 656

The "LINC00656 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00656 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets